TPCW
RPRX icon

TD Private Client Wealth’s Royalty Pharma RPRX Stock Holding History

TD Private Client Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.01K Buy
125
+56
+81% +$2.92K ﹤0.01% 1177
2026
Q1 		$3.31K Buy
69
+5
+8% +$219 ﹤0.01% 1222
2025
Q4 		$2.47K Buy
64
+15
+31% +$572 ﹤0.01% 1241
2025
Q3 		$1.73K Buy
49
+12
+32% +$434 ﹤0.01% 1260
2025
Q2 		$1.33K Hold
37
– – ﹤0.01% 1268
2025
Q1 		$1.15K Buy
37
+12
+48% +$380 ﹤0.01% 1276
2024
Q4 		$638 Buy
+25
New +$663 ﹤0.01% 1273

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Private Client Wealth's RPRX Position: Q2 2026 in Review

TD Private Client Wealth increased its Royalty Pharma (RPRX) stake by 81% in Q2 2026, buying an estimated $2.92K and bringing the position to 125 shares worth $7.01K. The position accounts for ﹤0.01% of the portfolio, ranked #1177.

TD Private Client Wealth first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • TD Private Client Wealth held 125 shares of Royalty Pharma worth $7.01K as of Q2 2026.
  • TD Private Client Wealth bought 56 Royalty Pharma shares in Q2 2026, an estimated $2.92K.
  • Royalty Pharma made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1177 holding.
  • TD Private Client Wealth first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.